================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q
(Mark One)

[X]  QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934

                For the quarterly period ended February 28, 2009

[_]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

                 For the transition period from _____ to _______

                       Commission File Number: 333-107179

                          CANCER DETECTION CORPORATION
             (Exact Name of Registrant as Specified in its Charter)

                    Nevada                                   98-0380519
       (State or other jurisdiction of                    (I.R.S. Employer

                 10965 Elizabeth Drive, Conifer, Colorado 80433
                 ----------------------------------------------
               (Address of Principal Executive Offices) (Zip Code)

        Registrant's telephone number including area code: (303) 908-4900

                                       N/A
--------------------------------------------------------------------------------
              Former name, former address, and former fiscal year,
                          if changed since last report

Indicate by check mark whether the registrant (1) filed all reports  required to
be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of 1934 during
the past 12 months (or for such shorter  period that the registrant was required
to file such reports),  and (2) has been subject to such filing requirements for
the past 90 days.                                         Yes [X]         No [_]

Indicate by check mark whether the registrant is a large  accelerated  filer, an
accelerated filer, a non-accelerated  filer, or a smaller reporting company. See
definition  of "large  accelerated  filer",  "accelerated  filer"  and  "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Larger accelerated filer [_]                       Accelerated filer [_]
Non-accelerated filer [_]                          Smaller reporting company [X]

Indicate by check mark whether registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).
Yes [_]    No [X]

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest  practicable  date:  16,653,124  shares of common
stock, par value $0.001, outstanding as of April 14, 2009.


================================================================================


<PAGE>

                          CANCER DETECTION CORPORATION

                                      Index

                                                                            Page

Item 1.   Financial Statements

          Consolidated Balance Sheets at February 28, 2009 (unaudited)
          and May 31, 2008                                                     1

          Consolidated Statements of Operations for the three months
          and nine months ended                                                2

          Consolidated Statements of Cash Flow for the nine months ended
          February 28, 2009 and February 29, 2008, and for the period
          from inception to February 28, 2009                                  3

          Notes to Consolidated Financial Statements (unaudited)               4

Item 2.   Management's Discussion and Analysis of Financial Condition and
          Results of Operations                                                9
Item 3.   Quantitative and Qualitative Disclosures About Market Risk          14
Item 4.   Controls and Procedures                                             13
Item 4T.  Controls and Procedures                                             14

Part II - OTHER INFORMATION
Item 1.   Legal Proceedings                                                   14
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds         14
Item 3.   Defaults Upon Senior Securities                                     15
Item 4.   Submission of Matters to a Vote of Security Holders                 15
Item 5.   Other Information                                                   15
Item 6.   Exhibits                                                            15

SIGNATURES                                                                    16


                                       i

<PAGE>

                         PART I - FINANCIAL INFORMATION

ITEM 1.  Financial Statements


<TABLE>
<CAPTION>

                         CANCER DETECTION CORPORATION AND SUBSIDIARY
                              (formerly Xpention Genetics, Inc.)
                                (A Development Stage Company)
                                 CONSOLIDATED BALANCE SHEETS


                                                                                February 28,           May 31,
                                                                                    2009                2008
                                                                               ----------------    ----------------
                                                                                 (Unaudited)
<S>                                                                            <C>                 <C>

                                          ASSETS

Current assets
     Cash and cash equivalents                                                            $ 28                $ 50
     Prepaid expenses                                                                    3,332                   -
                                                                               ----------------    ----------------
            Total assets                                                               $ 3,360                $ 50
                                                                               ================    ================


                         LIABILITIES AND STOCKHOLDERS' (DEFICIT)

Current liabilities
     Accounts payable and accrued expenses                                             $ 2,438           $ 149,664
     Accrued compensation                                                              416,000             344,000
     Accrued interest                                                                    2,580              17,344
     Advances from related parties                                                           -              15,000
     Notes payable, related party                                                            -             113,600
     Convertible debt                                                                   15,000              30,000
                                                                               ----------------    ----------------
            Total current liabilities                                                  436,018             669,608
                                                                               ----------------    ----------------

Stockholders' (deficit)
     Preferred stock, $0.001 par value, 10,000,000 shares authorized,
        none issued or outstanding                                                           -                   -
     Common stock, $0.001 par value, 100,000,000 shares authorized,
        16,353,124 and 2,998,826 shares issued and outstanding
        at February 28, 2009 and May 31, 2008, respectively                             16,353               2,999
     Additional paid-in capital                                                      1,288,298             978,101
     (Deficit) accumulated during the development stage                             (1,737,309)         (1,650,658)
                                                                               ----------------    ----------------
            Total stockholders' (deficit)                                             (432,658)           (669,558)
                                                                               ----------------    ----------------
            Total liabilities and stockholders' (deficit)                              $ 3,360                $ 50
                                                                               ================    ================

           The accompanying notes are an integral part of these financial statements.
</TABLE>


                                       1
<PAGE>

<TABLE>
<CAPTION>

                                   CANCER DETECTION CORPORATION AND SUBSIDIARY
                                       (Formerly Xpention Genetics, Inc.)
                                          (A Development Stage Company)
                                      CONSOLIDATED STATEMENTS OF OPERATIONS
                          For the three months and nine months ended February 28, 2009
                 and February 29, 2008, and for the period from Inception (October 13, 2004) to February 28, 2009
                                                   (Unaudited)



                                             Three Months Ended                   Nine Months Ended             October 13, 2004
                                       February 28,      February 29,      February 28,       February 29,       (Inception) to
                                           2009              2008              2009               2008         February 28, 2009
                                       -------------     -------------     -------------      -------------    -------------------
<S>                                    <C>               <C>               <C>                <C>              <C>

Revenues                                    $     -        $        -        $        -         $        -         $            -
                                       -------------     -------------     -------------      -------------    -------------------

Expenses
   Research and development                  14,661                 -            65,480             28,065              1,003,081
   General and administrative                36,441            33,610           129,476            112,845                685,589
                                       -------------     -------------     -------------      -------------    -------------------
        Total expenses                       51,102            33,610           194,956            140,910              1,688,670
                                       -------------     -------------     -------------      -------------    -------------------

Operating (loss)                            (51,102)          (33,610)         (194,956)          (140,910)            (1,688,670)
                                       -------------     -------------     -------------      -------------    -------------------

Other income (expense)
Interest expense                               (299)           (2,028)           (1,695)            (5,957)               (24,039)
Amortization of debt discount                     -            (2,071)                -           (126,200)              (134,600)
Contract settlement                         110,000                 -           110,000                  -                110,000
                                       -------------     -------------     -------------      -------------    -------------------
        Total other income (expense)        109,701            (4,099)          108,305           (132,157)               (48,639)
                                       -------------     -------------     -------------      -------------    -------------------

Net income (loss)                          $ 58,599         $ (37,709)        $ (86,651)        $ (273,067)          $ (1,737,309)
                                       =============     =============     =============      =============    ===================


Net income (loss) per common share:
   Basic and diluted                      $    0.00           $ (0.01)       $    (0.01)        $    (0.09)
                                       =============     =============     =============      =============

Weighted average shares outstanding:
   Basic and diluted                     14,642,013         2,998,826         9,188,549          2,998,826
                                       =============     =============     =============      =============

   The accompanying notes are an integral part of these financial statements.
</TABLE>



                                       2
<PAGE>

<TABLE>
<CAPTION>

                      CANCER DETECTION CORPORATION AND SUBSIDIARY
                          (formerly Xpention Genetics, Inc.)
                             (A Development Stage Company)
                         CONSOLIDATED STATEMENTS OF CASH FLOWS
          For the nine months ended February 28, 2009 and February 29, 2008,
       and for the period from Inception (October 13, 2004) to February 28, 2009
                                      (Unaudited)


                                                                                          October 13, 2004
                                                            Nine Months Ended              (Inception) to
                                                    February 28, 2009  February 29, 2008  February 28, 2009
                                                    ---------------    ----------------   ------------------
<S>                                                 <C>                <C>                <C>

Cash flows from operating activities:
      Net (loss)                                         $ (86,651)         $ (273,067)        $ (1,737,309)
                                                    ---------------    ----------------   ------------------
      Adjustments to reconcile net (loss) to
          net cash used in operating  activities:
          Contract settlement                             (110,000)                  -             (110,000)
          Stock based compensation                           5,500                   -              376,900
          Amortization of debt discount                          -             126,200              134,600
      Changes in operating assets and liabilities:
          Prepaid expenses                                  (3,332)             (4,781)              (3,332)
          Accounts payable and accrued expenses             34,461             106,478              545,469
                                                    ---------------    ----------------   ------------------
      Total adjustments                                    (73,371)            227,897              943,637
                                                    ---------------    ----------------   ------------------

          Cash flows (used in) operating activities       (160,022)            (45,170)            (793,672)
                                                    ---------------    ----------------   ------------------

Cash flows from investing activities:
                                                    ---------------    ----------------   ------------------
          Cash flows (used in) investing activities              -                   -                    -
                                                    ---------------    ----------------   ------------------

Cash flows from financing activities:
      Proceeds from note payable                                 -               5,600              113,600
      Proceeds from convertible debt                             -                   -               30,000
      Principal payments on convertible debt               (15,000)                  -              (15,000)
      Advances from related parties                         28,750              15,000               53,750
      Repayment of advances from related parties           (43,750)                  -              (53,750)
      Proceeds from issuance of common stock               190,000                   -              665,100
                                                    ---------------    ----------------   ------------------
          Cash flows provided by financing activities      160,000              20,600              793,700
                                                    ---------------    ----------------   ------------------

Net (decrease) increase in cash and equivalents                (22)            (24,570)                  28

Cash and cash equivalents, beginning of period                  50              24,707                    -
                                                    ---------------    ----------------   ------------------

Cash and cash equivalents, end of period                      $ 28               $ 137                 $ 28
                                                    ===============    ================   ==================

Supplemental cash flow information:

        Income taxes paid                                      $ -                 $ -                  $ -
                                                    ===============    ================   ==================

        Interest paid                                      $ 2,009                 $ -              $ 7,009
                                                    ===============    ================   ==================

Non-cash investing and financing activities:

      Conversion of convertible debt and accrued
          interest to common shares                      $ 128,051                 $ -            $ 128,051
                                                    ===============    ================   ==================

      The accompanying notes are an integral part of these financial statements.
</TABLE>

                                       3
<PAGE>

                   CANCER DETECTION CORPORATION AND SUBSIDIARY
                       (Formerly Xpention Genetics, Inc.)
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                February 28, 2009
                                   (Unaudited)

NOTE  1.  ORGANIZATION,  BASIS  OF  PRESENTATION,  AND  SUMMARY  OF  SIGNIFICANT
ACCOUNTING POLICIES

Interim Financial Information

         The interim consolidated financial statements included herein have been
prepared  by the  Company,  without  audit,  in  accordance  with the  rules and
regulations of the Securities and Exchange  Commission  ("SEC") pursuant to Item
210 of Regulation S-X.  Certain  information and footnote  disclosures  normally
included  in  financial   statements  prepared  in  accordance  with  accounting
principles  generally  accepted in the United States of America ("US GAAP") have
been condensed or omitted pursuant to such SEC rules and  regulations,  although
the Company  believes  that the  disclosures  included  are adequate to make the
information presented not misleading.

         In management's  opinion, the consolidated balance sheet as of February
28, 2009 (unaudited),  the unaudited  consolidated  statements of operations for
the three month and nine month periods ended  February 28, 2009 and February 29,
2008, and the unaudited consolidated statements of cash flows for the nine month
periods ended February 28, 2009 and February 29, 2008, contained herein, reflect
all  adjustments,  consisting  solely  of  normal  recurring  items,  which  are
necessary  for the fair  presentation  of our  financial  position,  results  of
operations,  and cash flows on a basis consistent with that of our prior audited
consolidated  financial  statements.  However,  the  results of  operations  for
interim  periods may not be  indicative  of results to be expected  for the full
fiscal year. Therefore, these financial statements should be read in conjunction
with  the  audited  financial  statements  and  notes  thereto  and  summary  of
significant  accounting  policies  included in the Company's Form 10-KSB for the
year ended May 31, 2008.

Reverse Stock Split and Name Change

         On September 10, 2008, the Board of Directors of the Company approved a
reverse  stock  split of the common  stock in the ratio of 1 for 20 and the name
change  from  Xpention  Genetics,  Inc.  to Cancer  Detection  Corporation.  The
resolutions became effective September 17, 2008, when the State of Nevada issued
a  Certificate  of  Amendment  to  the  Company's   Articles  of  Incorporation.
Stockholders holding a majority of outstanding shares approved the reverse split
and the name change  amendment on July 25, 2008, by written consent in lieu of a
meeting of stockholders.  As a result of the Company's name change,  its trading
symbol on the Over-the-Counter Bulletin Board was changed to "CCDC."

         All share and per share amounts  presented herein have been restated to
reflect the effect of the 1 for 20 reverse stock split approved on September 10,
2008.


Organization

         Cancer  Detection   Corporation  (the  "Company")   (formerly  Xpention
Genetics,  Inc.)  is a  Nevada  corporation  that  resulted  from  the  business
combination  between  Xpention,  Inc. and Bayview  Corporation  that occurred in
March, 2005. For accounting  purposes,  the date of inception for the Company is
October 13, 2004, the date that Xpention, Inc. was incorporated. The Company has
been in the  development  stage since its formation and has not yet realized any
revenues  from  its  planned  operations.  It is  engaged  in the  biotechnology

                                       4
<PAGE>

industry to develop both  immunological and molecular tests for cancer detection
in  animals  and  humans as well as  therapeutic  vaccines  and other  treatment
methods for both canine and human cancers. The Company's fiscal year ends on May
31st.

Basis of Presentation

         Cancer Detection Corporation  represents the result of a merger between
Bayview Corporation ("Bayview"), a public company, and Xpention, Inc., a private
company. During March 2005, Bayview issued 715,000 shares of its common stock to
the sole  shareholder  of  Xpention,  Inc. in exchange for all of the issued and
outstanding common shares of Xpention, Inc. pursuant to an Agreement and Plan of
Reorganization  (the  "Merger").  In addition,  concurrent  with the exchange of
shares,  Bayview  changed its name to Xpention  Genetics,  Inc.,  whose name has
subsequently been changed to Cancer Detection Corporation as described above.

         For accounting purposes, this acquisition of Xpention, Inc. by Bayview,
a non-operating  entity,  represents a reverse acquisition under which Xpention,
Inc. is  recognized as the  accounting  acquirer.  In substance,  the Merger was
recorded as a capital  transaction by the issuance of 2,127,159 shares of common
stock by the  Company  for all of the issued and  outstanding  common  shares of
Bayview. No goodwill or other intangible assets were recorded and the historical
financial  statements  as of and prior to the  acquisition  date  represent  the
operations of Xpention, Inc.

         Xpention, Inc. (a wholly-owned subsidiary of  the Company) was  incorp-
orated in the State of  Colorado  on  October  13,  2004.  Since its  inception,
Xpention,  Inc. has participated in the  biotechnology  industry to develop both
immunological  and molecular tests for cancer detection in animals and humans as
well as  therapeutic  vaccines and other  treatment  methods for both canine and
human cancers.

         Bayview was incorporated in the State of Nevada,  on September 5, 2002.
From  inception  until February 28, 2005,  Bayview was primarily  engaged in the
acquisition and exploration of mining  properties,  but had ceased operations by
February  28, 2005.  As of the date of the Merger,  Bayview had no assets and no
operations and has been treated as the acquired company for accounting purposes.

Development Stage Company

         The Company  presents its financial  statements in conformity  with the
accounting  principles  generally  accepted in the United States of America that
apply to enterprises that are establishing  their  operations.  As a development
stage enterprise, the Company must utilize accounting principles consistent with
those required of an established enterprise, and, in addition, must disclose the
deficit  accumulated during the development stage and the cumulative  statements
of  operations  and cash flows from  commencement  of  development  stage to the
current balance sheet date.

Basis of Consolidation

         The  consolidated  financial  statements  include  the  accounts of the
Company  and  its  wholly-owned  subsidiary,   Xpention,  Inc.  All  significant
intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

         The  preparation  of financial  statements in  conformity  with US GAAP
requires  management to make estimates and assumptions  that affect the reported
amount of assets  and  liabilities  and  disclosure  of  contingent  assets  and
liabilities at the date of the financial  statements and the reported amounts of
revenues and expenses during the reporting  period.  Management  routinely makes
judgments  and  estimates  about the  effects  of  matters  that are  inherently

                                       5
<PAGE>

uncertain. Management bases its estimates and judgments on historical experience
and on various  other  factors  that are  believed  to be  reasonable  under the
circumstances,  the results of which form the basis for making  judgments  about
the carrying values of assets and liabilities that are not readily apparent from
other  sources.  Estimates  and  assumptions  are revised  periodically  and the
effects of revisions are reflected in the financial  statements in the period it
is determined to be necessary. Actual results could differ from these estimates.

Per Share Amounts

         SFAS 128, "Earnings Per Share," provides for the calculation of "Basic"
and "Diluted"  earnings per share. Basic earnings per share includes no dilution
and is computed by dividing net income (or loss) by the weighted-average  number
of shares outstanding during the period. Diluted earnings per share reflects the
potential  dilution  of  securities  that  could  share in the  earnings  of the
Company, assuming the issuance of an equivalent number of common shares pursuant
to options,  warrants,  or convertible debt  arrangements.  Diluted earnings per
share is not shown for  periods in which the  Company  incurs a loss  because it
would be  anti-dilutive.  Similarly,  potential common stock equivalents are not
included in the calculation if the effect would be anti-dilutive.

         All share and per share amounts  presented herein have been restated to
reflect the effect of the 1 for 20 reverse stock split approved on September 10,
2008.

Recent Accounting Pronouncements

         There were no accounting standards and interpretations  issued recently
which  are  expected  to a have a  material  impact on the  Company's  financial
position, operations or cash flows.

NOTE 2.  GOING CONCERN

         The accompanying  consolidated  financial statements have been prepared
in conformity with US GAAP, which contemplates  continuation of the Company as a
going concern.

         The  Company  is in its  development  stage  and has not yet  generated
revenues from operations.  It has experienced losses from operations as a result
of its investment  necessary to achieve its operating plan,  which is long-range
in nature.  During the nine months ended February 28, 2009, the Company incurred
a net loss of $86,651, and has incurred a cumulative net loss since inception of
$1,737,309.  At February 28, 2009, the Company had a working capital deficit and
stockholders'  deficit of  $432,658  and has no revenue  generating  operations.
These  conditions  raise  substantial  doubt about the ability of the Company to
continue as a going concern.

         Management  does  not  believe  that  the  Company's   current  capital
resources  will be sufficient  to fund its operating  activity and other capital
resource  demands  during fiscal year 2009 and is currently  seeking  additional
resources.  The  Company's  ability to continue as a going concern is contingent
upon its  ability to obtain  capital  through  the sale of equity or issuance of
debt, joint venture or sale of its assets, and ultimately  attaining  profitable
operations.  There is no assurance that the Company will be able to successfully
complete any one of these activities. Recent events in worldwide capital markets
may  make it more  difficult  for  the  Company  to  obtain  additional  capital
resources.

         The financial  statements do not include any adjustments to reflect the
possible future effects on the  recoverability  and  classification of assets or
the amounts and  classification of liabilities that may result from the possible
inability of the Company to continue as a going concern.

                                       6
<PAGE>

NOTE 3.  NOTES PAYABLE, RELATED PARTY

         Effective  June 30, 2008,  The Regency  Group,  LLC  ("Regency  Group")
converted the outstanding  principal of $113,600 and accrued interest of $14,451
into 1,829,298 (post-split) shares of common stock.

NOTE 4.  CONVERTIBLE DEBT

         Effective January 5, 2007, the Company issued convertible debentures in
the aggregate  principal  amount of $30,000 to two debt holders.  The debentures
bear interest at 8% per annum and were  originally  due on January 5, 2008.  The
due date was subsequently  extended,  as discussed below. The debenture  holders
may convert the principal and accrued  interest into the Company's  common stock
at a rate of $0.20 per share.  Regency  Group holds  $15,000 of the  convertible
debt.

         Both debt  holders  agreed to  extend  the due date of the  convertible
debentures  to April 30, 2008.  During the nine months ended  February 28, 2009,
the Company repaid one debt holder the principal balance of $15,000 plus accrued
interest of $2,009.  Regency  Group agreed to extend the due date of the $15,000
principal  balance held by them to December 31, 2008, and  subsequently to April
30, 2009.

NOTE 5.  STOCKHOLDERS' (DEFICIT)

         On September 10, 2008, the Board of Directors  approved a resolution to
affect a 1 for 20 reverse  stock split,  which became  effective  September  17,
2008,  when the  State  of  Nevada  issued a  Certificate  of  Amendment  to the
Company's  Articles of  Incorporation.  One share of common  stock was issued in
replacement of each 20 shares  outstanding as of July 24, 2008, the record date,
and the  number  of  authorized  shares  did not  change.  All of the  financial
information in this report has been adjusted to reflect the effect of this 1 for
20 reverse stock split.  As a result of the Company's  name change,  its trading
symbol on the Over-the-Counter Bulletin Board was changed to "CCDC".

         Effective  June 30, 2008,  the Company  issued  1,829,298  (post-split)
shares of common stock for the conversion of $113,600 in  outstanding  principal
of notes payable and the related accrued interest of $14,451.

         Effective  September  10,  2008,  the Company  recorded the issuance of
25,000  (post-split)  shares of its common stock for investor relations services
performed in connection  with the reverse  stock split and the name change.  The
services  were valued at $5,500,  an amount  consistent  with the quoted  market
value of $0.22 per share on September 10, 2008.

         In October 2008, the Company issued a  total  of 7,500,000 (post-split)
shares of its common stock in a private  placement to two  stockholders at $0.02
per share for cash proceeds of $150,000.

         In January 2009, the  Company issued a  total of 4,000,000 (post-split)
shares of its common stock in a private  placement to two  stockholders at $0.01
per share for cash proceeds of $40,000.

NOTE 6.  COMMITMENTS

         Effective  October 6, 2008,  the Company  entered into a revised  Assay
Development Proposal with Future Focus, an independent testing organization. The
proposal is composed of 4 major phases with an estimated  total cost of $82,000.
Phase I, which  consists of testing with  commercially  available  antibodies to
p65, was completed  during December 2008. Work on Phase II has not commenced and
is  contingent  upon  certain  results  from Phase IV.  Phase III,  which is the
preparation of recombinant  monoclonal  antibodies used in the research has been
completed.  Phase IV  consisting  of assay  formulation  and canine serum sample

                                       7
<PAGE>

analysis has begun.  The Company has expended  $29,770  under the contract as of
February 28, 2009, and has a remaining commitment of approximately $52,000.

     In September,  2008, the Company amended its Patent and Technology  License
Agreement  with the Board of Regents of The  University  of Texas System and The
University  of Texas M. D.  Anderson  Cancer Center to extend the time frame for
commercialization  of a veterinary product an additional two years and to extend
the time frame for commercialization of a human diagnostic product an additional
three years,  among other  changes.  It is expected that these  extensions  will
allow the Company to complete its research and begin marketing activities within
the  milestones  established  in  the  amended  Agreement.  The  company  paid a
non-refundable  documentation  fee of $25,000  and is  required to pay an annual
maintenance  fee of $25,000  within thirty days of the first  anniversary of the
amendment  effective  date. The annual  maintenance fee will increase by $25,000
per year and either party can terminate the agreement after two years.

NOTE 7.  SEC ENFORCEMENT ACTION

         During  2008,  the  Company  was  informed  that  the  staff of the SEC
intended to recommend that a civil  injunctive  action be commenced  against the
Company  for  alleged  violations  of the  Securities  Act of 1933.  The alleged
violations  are regarding the proceeds from the sales of the Company's  stock in
2005. On January 30, 2009, the Company submitted an Offer of Settlement  without
admitting or denying the SEC's findings.  On March 9, 2009, the SEC accepted the
Offer of Settlement and imposed an order under which the Company agreed to cease
and desist from  committing or causing any violations and any future  violations
of Sections 5(a) and 5(c) of the Securities Act.

NOTE 8.  RELATED PARTY TRANSACTIONS

         During the nine months ended  February 28, 2009,  the Company  received
cash advances of $28,750 from stockholders of the Company.  The advances did not
bear any  interest and were due upon  demand.  All of the  advances  were repaid
prior to February 28, 2009.

NOTE 9.  CONTRACT SETTLEMENT

         Effective February 27, 2009, the Company reached agreement with a third
party  research   organization   to  reduce  amounts  payable  to  the  research
organization  by $110,000.  The agreement  was recorded  during the period ended
February 28, 2009 as a contract settlement gain of $110,000.

NOTE 10.  SUBSEQUENT EVENTS

         Subsequent  to February 28, 2009,  the Company  agreed to issue 300,000
shares  of  common  stock in a  private  placement  at $0.01  per share for cash
proceeds of $3,000.

         Subsequent  to February 28, 2009,  the Regency  Group agreed to further
extend the maturity date of its $15,000  convertible  debt to April 30, 2009, in
exchange  for a reduction in the  conversion  rate from $0.20 per share to $0.02
per share.


                                       8
<PAGE>

ITEM 2. Management's  Discussion and Analysis of Financial Condition and Results
of Operation

         The  following  discussion  should  be read  in  conjunction  with  our
unaudited financial statements and notes thereto,  which are included herein. In
connection  with,  and because we desire to take advantage of, the "safe harbor"
provisions of the Private  Securities  Litigation Reform Act of 1995, we caution
readers regarding certain forward looking statements in the following discussion
and  elsewhere  in this  report  and in any other  statement  made by, or on our
behalf,  whether  or not in future  filings  with the  Securities  and  Exchange
Commission.  Forward-looking  statements  are statements not based on historical
information and which relate to future operations, strategies, financial results
or other  developments.  Forward looking  statements are necessarily  based upon
estimates and assumptions that are inherently  subject to significant  business,
economic and  competitive  uncertainties  and  contingencies,  many of which are
beyond our control and many of which, with respect to future business decisions,
are subject to change.  These  uncertainties and contingencies can affect actual
results and could cause actual results to differ materially from those expressed
in any forward  looking  statements  made by, or on our behalf.  We disclaim any
obligation to update forward-looking statements.

         The  independent  registered  public  accounting  firm's  report on the
Company's financial  statements as of May 31, 2008, and for each of the years in
the  two-year  period  then  ended,   includes  a  "going  concern"  explanatory
paragraph,  that  describes  substantial  doubt about the  Company's  ability to
continue  as a going  concern.  Management's  plans  in  regard  to the  factors
prompting the  explanatory  paragraph are discussed  below and also in Note 2 to
the unaudited interim financial statements.

Plan of Operation

         The Company, through Xpention, Inc, its wholly-owned subsidiary,  holds
the exclusive  worldwide  license to a patented  technology for the detection of
cancer  based on a tumor marker  known as "p65" which has been  demonstrated  to
have  elevated  levels in the blood of canine and human cancer  conditions.  The
tumor marker "p65" is believed to be a protein required in the early development
of  numerous  cancers  and  appears  from  early  research  to  provide a strong
indication of tumor growth in both canines and humans. It also appears to have a
direct  correlation  to tumor  size/mass  making it a promising  marker for both
early  detection  of  malignant  tumor  formation  as well as a useful  tool for
monitoring  therapy and remission.  We plan to develop an immunological  test as
well as a molecular  assay for  detection of cancer in canines.  We also plan to
develop both immunological and molecular tests for detection of human cancers as
well as therapeutic treatments and vaccines.

         In September,  2008,  Xpention,  Inc. amended its Patent and Technology
License  Agreement  with the Board of Regents of The  University of Texas System
and The University of Texas M. D. Anderson  Cancer Center  ("UTMDACC") to extend
the time frame for  commercialization  of a veterinary product an additional two
years and to extend the time frame for  commercialization  of a human diagnostic
product an  additional  three years,  among other  changes.  It is expected that
these  extensions  will allow the Company to  complete  its  research  and begin
marketing activities within the milestones established in the amended Agreement.

         We contract  with third  party  research  organizations  to conduct our
research  activities.  During June 2007, we entered into an Assay Revalidation /
Redevelopment  Proposal with Future Focus, an independent testing  organization.
The project calls for third party validation of the research  results  presented
in the final report from the  University of Texas Health  Science  Center at San
Antonio  ("UTHSCSA")  and  technology  transfer of the current  assay plus assay
reformatting  and sample  analysis.  On August 15, 2007,  we announced  that the
researchers had been unable to replicate the results obtained at UTHSCSA.

                                       9
<PAGE>

         On October  6, 2008,  the Company entered into a revised Assay Develop-
ment  Proposal with Future  Focus,  an  independent  testing  organization.  The
proposal is composed of 4 major phases.  Phase I, which consists of testing with
commercially  available  antibodies to p65, was completed in December 2008. Work
on Phase II has not commenced and is contingent  upon certain results from Phase
IV.  Phase  III,  which is a  commercial  contract  with AbD  Serotec,  a German
biotechnology  company, for the preparation of recombinant monoclonal antibodies
used in the research has been completed as well. Future Focus has now begun work
on Phase IV, consisting of assay formulation and canine serum sample analysis.

         As a result of the revalidation  results,  we are reviewing our planned
research  activities  for the  development  of an  immunological  canine  cancer
detection   test.   We  also   continue   to   evaluate   various   options  for
commercialization  of  products;  however,  it is not  anticipated  that we will
generate any revenues from  commercialization  of our technology during the next
twelve months.

         On September 10, 2008, the Board of Directors of the Company approved a
reverse  stock  split of the common  stock in the ratio of 1 for 20 and the name
change  from  Xpention  Genetics,  Inc.  to Cancer  Detection  Corporation.  The
resolutions were effective September 17, 2008, when the State of Nevada issued a
Certificate   of  Amendment  to  the   Company's   Articles  of   Incorporation.
Stockholders  holding a majority of  theoutstanding  shares approved the reverse
split and the name change amendment on July 25, 2008, by written consent in lieu
of a meeting of  stockholders.  As a result of the  Company's  name change,  its
trading symbol on the Over-the-Counter Bulletin Board was changed to "CCDC."

         During  2008,  the  Company  was  informed  that  the  staff of the SEC
intended to recommend that a civil  injunctive  action be commenced  against the
Company  for  alleged  violations  of the  Securities  Act of 1933.  The alleged
violations  were  regarding  proceeds from the sales of the  Company's  stock in
2005. On January 30, 2009, the Company submitted an Offer of Settlement  without
admitting or denying the SEC  findings.  On March 9, 2009,  the SEC accepted the
Offer of Settlement and imposed an order under which the Company agreed to cease
and desist from  committing or causing any violations and any future  violations
of Sections 5(a) and 5(c) of the Securities Act.

Liquidity and Capital Resources

         As of February 28, 2009,  our working  capital  deficit of $432,658 was
comprised of current assets of $3,360 and current liabilities of $436,018.  This
represents an improvement in working capital of $236,900 compared to the deficit
of $669,558  at fiscal  year end May 31,  2008.  Our  working  capital  position
improved  primarily  because (i) we received  cash proceeds of $190,000 from the
private  placement  of  11,500,000  shares  of  common  stock,  (ii) a  creditor
converted certain indebtedness into common stock, and (iii) a creditor agreed to
reduce amounts due under a research contract by $110,000.

         Management  does  not  believe  that  the  Company's   current  capital
resources  will be sufficient  to fund its operating  activity and other capital
resource demands for the next twelve months.  Our ability to continue as a going
concern is  contingent  upon our ability to obtain  capital  through the sale of
equity or  issuance of debt,  joint  venture or sale of assets,  and  ultimately
attaining profitable  operations.  There is no assurance that we will be able to
successfully  complete any one of these  activities.  Recent events in worldwide
capital markets may make it more difficult for us to obtain  additional  capital
resources.

         We are presently  seeking  additional  financing to provide  sufficient
funds for payment of amounts due under research contracts as well as accrued but
unpaid  professional  fees  and  administrative  expenses  and to  fund  ongoing
research and operations.

         We  have  never  received   revenue  from  our   operations.   We  have
historically  relied on equity and debt financings to fund our capital  resource
requirements.  We have experienced net losses since inception. We do not believe
that we are a candidate  for  conventional  debt  financing and we have not made

                                       10
<PAGE>

arrangements to borrow funds under a working capital line of credit.  We will be
dependent on  additional  financing  to continue  our  research and  development
efforts.

         All of our investment in research and  development  activities has been
expensed,  and does not appear as an asset on our balance sheet.  From inception
to February 28, 2009, we have spent  $1,003,081 on our research and  development
efforts to commercialize the "p65" technology.

         All of our capital  resources  to date have been  provided  through the
sale  of  equity  securities,   proceeds  from  notes  payable  and  convertible
debentures,  and advances from related parties.  From inception through February
28, 2009, we received  $665,100 in cash through issuance of our common stock. In
addition,   we  received  cash  proceeds  of  $143,600  from  various  borrowing
arrangements.  Since we have not  generated  any cash from  operations,  we have
relied on sale of equity and borrowings to fund all of our capital needs.

         Our ability to pay  accounts  payable and  accrued  expenses  and repay
borrowings is dependent upon receipt of new funding.  Certain  stockholders have
periodically advanced funds to us to meet our working capital needs. The related
parties are under no obligations to continue these advances.  As of February 28,
2009, all advances  received from related parties had been repaid and there were
no outstanding balances.

         Net cash used in operating  activities  was  $160,022,  during the nine
months  ended  February 28,  2009,  compared to $45,170,  during the nine months
ended  February  29, 2008,  an increase of $114,852.  Net cash used in operating
activities is closely  correlated to cash provided by financing  activities.  We
used the proceeds from our  financing  activities to fund research and operating
expenses and reduce accounts payable.

         During the nine months ended February 28, 2009 and 2008,  the Company's
investment activities neither provided nor used any funds.

         Net cash provided by financing  activities during the nine months ended
February 28, 2009, was $160,000 compared to $20,600 during the nine months ended
February 29, 2008.

         During the nine months ended  February 28,  2009,  we issued  7,500,000
shares of our common stock at $0.02 per share for cash proceeds of $150,000, and
we issued an additional  4,000,000 shares of our common stock at $0.01 per share
for cash proceeds of $40,000.  We also received advances from related parties of
$28,750.  We used cash in  financing  activities  to repay  advances  to related
parties of $43,750 and retire convertible debt of $15,000.

         Our  financing  activities  during the nine months  ended  February 29,
2008,  provided  proceeds  from a note  payable  of $5,600 and  advances  from a
related party of $15,000.

         In a non-cash  transaction  effective  June 30, 2008, The Regency Group
LLC (Regency Group) converted $113,600 of outstanding principal on notes payable
and $14,451 of related  accrued  interest  into  1,829,298  shares of our common
stock.  During the nine months ended  February 28, 2009, the due date of $15,000
convertible  debt  payable to Regency  Group was  extended to December 31, 2008.
Subsequent  to February 28,  2009,  Regency  Group agreed to further  extend the
maturity date to April 30, 2009,  in exchange for a reduction in the  conversion
rate from $0.20 per share to $0.02 per share.

         In another non-cash  transaction  effective  February 28, 2009, a third
party  research  organization  agreed to reduce  the  amounts  due to it under a
research contract by $110,000.

                                       11
<PAGE>

Results of Operations

For the Three  Months  Ended  February  28, 2009  Compared to Three Months Ended
February 29, 2008

         We are considered a development stage company for accounting  purposes,
since we have not  received  any  revenues  from  operations.  We are  unable to
predict with any degree of accuracy when that situation  will change.  We expect
to incur losses until such time,  if ever, as we begin  generating  revenue from
operations.

         For the three months ended February 28, 2009, we recorded net income of
$58,599,  or $0 per share,  compared to a net loss of  $(37,709)  or $(0.01) per
share for the three months ended February 29, 2008, a difference of $96,308. The
three months  ended  February 28, 2009  included a contract  settlement  gain of
$110,000.  Absent the gain,  the  reported  net loss for the three  months ended
February 28, 2009, would have been $(51,401), or $(0) per share.

         During the three  months ended  February 28, 2009 and 2008,  we did not
recognize any revenues from our operational activities.

         Research and development  costs were $14,661 for the three months ended
February  28, 2009.  During the three months ended February 28, 2009, we did not
incur any research and  development  costs.  Our use of third party research and
testing partners may result in significant  variations in the expenses  reported
in each period.  The costs  incurred  during the three months ended February 28,
2009 represented amounts paid to third party testing organizations.

         General and  administrative  expense increased to $36,441 for the three
months ended  February 28, 2009,  compared to $33,610  during the same period of
2008. The increase of $2,831 includes an increase of investor  relations expense
of $1,565 and an increase  in legal and  accounting  costs of $1,769.  Increased
investor relations and legal and accounting expenses were incurred in connection
with the Company's  name change and reverse stock split and increase in research
activity. The primary components of general and administrative expense are costs
accrued for  compensation,  professional  fees  associated  with our status as a
public  company,  and the premium costs of D&O  insurance.  Directors & Officers
(D&O)  insurance  decreased  by $1,450,  or 30%, as a result of obtaining a less
costly policy.

         Interest expense was $299 for the three months ended February 28, 2009,
compared to $4,099 for the three months  ended  February 29, 2008, a decrease of
$3,800 or 93%.  Included in interest expense in 2008 is the amortization of debt
discount in the amount of $2,071 related to the beneficial conversion feature of
the convertible  debentures issued during 2007. The remainder of the decrease in
interest  expense  is  attributable  to a  reduction  in  outstanding  principal
balances of notes payable.

For the Nine Months Ended  February  28, 2009  Compared to the Nine Months Ended
February 29, 2008

         For the nine months ended  February 28, 2009, we recorded a net loss of
$(86,651) or $(0.01) per share, compared to a net loss for the nine months ended
February 29, 2008 of $(273,067) or $(0.09) per share,  a difference of $186,416.
The 2009 period  included a contract  settlement  gain of  $110,000.  Absent the
gain,  the reported  net loss for the nine months ended  February 28, 2009 would
have been $(196,651), or $(0.02) per share.

         During the nine  months  ended  February  28,  2009 and 2008 we did not
recognize any revenues from our operational activities.

         Research and  development  costs  increased to $65,480  during the nine
months ended  February 28, 2009,  compared to $28,065  incurred  during the nine

                                       12
<PAGE>

months ended February 29, 2008. The increase of $37,415 includes $25,000 paid to
UTMDACC in connection with the amendment to the License  Agreement  discussed in
the Plan of Operations. The remaining amounts during both periods were for third
party testing costs incurred to validate the results of the research report from
UTHSCSA.  Our use of third party  research  and testing  partners  can result in
significant variations in the expenses reported in each period.

         General and administrative  expenses increased to $129,476 for the nine
months ended February 28, 2009,  compared to $112,845  during the  corresponding
period of 2008.  The overall  increase of $16,631  includes  increased  investor
relations expense of $9,851 and stock compensation  costs of $5,500.  During the
nine months ended  February 28, 2009, we agreed to issue 25,000 shares of common
stock to an  investor  relations  consultant  valued at  $5,500.  The  increased
expenses were a result of the Company's  name change,  reverse stock split,  and
increased efforts to communicate with its investors.  The primary  components of
general  and   administrative   expense  are  costs  accrued  for  compensation,
professional  fees  associated  with our  status  as a public  company,  and the
premium costs of D&O insurance.

         Interest   expense,   including  the  amortization  of  debt  discount,
decreased  to $1,695 for the nine months  ended  February  28, 2009  compared to
$132,157  for the nine months  ended  February 29, 2008, a decrease of $130,462.
Interest  expense  reported during the 2008 period included the  amortization of
debt discount of $126,200,  related to the beneficial  conversion feature of the
convertible  indebtedness.  The costs  were not  repeated  during  2009.  As the
amortization costs are a non-cash item, they do not impact our liquidity.

         The remainder of the decrease in interest  expense is attributable to a
reduction in outstanding principal balances of notes payable.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

            As a "smaller reporting company" as defined by Item 10 of Regulation
S-K, the Company is not required to provide information required by this Item.

ITEM 4.  CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

            We have adopted and maintain  disclosure controls and procedures (as
such term is defined  in Rules  13a-15(e)  and  15d-15(e)  under the  Securities
Exchange  Act of 1934,  as amended  (the  "Exchange  Act")) that are designed to
ensure that  information  required  to be  disclosed  in our  reports  under the
Exchange Act, is recorded,  processed,  summarized and reported  within the time
periods  required  under the SEC's rules and forms and that the  information  is
gathered and  communicated  to our  management,  including  our Chief  Executive
Officer  (Principal  Executive  Officer) and Chief Financial Officer  (Principal
Financial  Officer),  as appropriate,  to allow for timely  decisions  regarding
required disclosure.

            As  required  by SEC Rule  15d-15(b),  our Chief  Executive  Officer
("CEO") and Chief  Financial  Officer  ("CFO")  carried out an evaluation of the
effectiveness  of the  design  and  operation  of our  disclosure  controls  and
procedures  pursuant  to  Exchange  Act Rule  15d-14 as of the end of the period
covered by this report.  As a result of this  evaluation,  we concluded that our
disclosure controls and procedures were not effective at May 31, 2008.

            Our disclosure controls and procedures failed to detect the omission
of a required  report in our filing as of May 31, 2008.  On April 15,  2009,  we
filed an amended Form 10-KSB to correct this omission.

            During the nine months ended February 28, 2009,  we have implemented
steps to strengthen our disclosure  controls and procedures,  to evaluate and to
remedy  deficiencies,  and to test the  controls  and  procedures  on a periodic
basis.  Such steps  included  our CEO and CFO  modifying  his review  process to
capture  recent and pending  changes in disclosure  requirements.  The Company's
small size renders it impractical to assign disclosure control duties to a staff
person. As a compensating  control, we will increase our use of outside advisors
to improve the  effectiveness  of our  disclosure  controls and  procedures.  At
February 28, 2009, we have concluded that our disclosure controls are effective.

                                       13

<PAGE>

ITEM 4T.  Controls and Procedures

Management's Quarterly Report on Internal Control over Financial Reporting.

         Management is responsible for  establishing  and  maintaining  adequate
internal  control  over  financial  reporting,  as such term is  defined  in the
Securities   Exchange  Act  of  1934  Rule   13a-15(f).   Our  Chief   Executive
Officer/Acting   Chief  Financial   Officer   conducted  an  evaluation  of  the
effectiveness  of our internal  control over  financial  reporting  based on the
framework in Internal Control - Integrated Framework, issued by the Committee of
Sponsoring Organizations of the Treadway Commission ("COSO Framework").

         Management's  assessment  of the  effectiveness  of the small  business
issuer's  internal  control over financial  reporting is as of the quarter ended
February 28, 2009. We believe that internal control over financial  reporting is
effective.  We have not identified any, current material weaknesses  considering
the  nature  and  extent of our  current  operations  and any risks or errors in
financial reporting under current operations.

         Because of its inherent  limitations,  internal  control over financial
reporting  may not prevent or detect  misstatements.  Also,  projections  of any
evaluation  of  effectiveness  to future  periods  are  subject to the risk that
controls may become  inadequate  because of changes in  conditions,  or that the
degree of compliance with the policies or procedures may deteriorate.

         This  quarterly  report does not include an  attestation  report of the
Company's  registered  public  accounting firm regarding  internal  control over
financial  reporting.  Management's report was not subject to attestation by the
Company's  registered  public accounting firm pursuant to temporary rules of the
Securities  and  Exchange  Commission  that permit the  Company to provide  only
management's report in this annual report.

         There was no change in our internal  control over  financial  reporting
that  occurred  during the fiscal  quarter  ended  February 28,  2009,  that has
materially affected,  or is reasonably likely to materially affect, our internal
control over financial reporting.


                           PART II - OTHER INFORMATION


Item 1.  LEGAL PROCEEDINGS

         No legal  proceedings  are  pending  or  threatened  to the best of our
knowledge.

Item 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

         On January  3,  2009,  we sold  2,000,000  shares of common  stock to a
private investment firm for cash proceeds of $20,000.

         On January 12,  2009,  we sold  2,000,000  shares of common  stock to a
private investor for cash proceeds of $20,000.

Exemption From Registration Claimed

         All of the sales by the  Company of its  unregistered  securities  were
made by the Company in reliance upon Section 4(2) of the Securities Act of 1933,
as amended (the "1933 Act"). All of the individuals and/or entities listed above
that purchased the unregistered securities were all known to the Company and its
management,  through pre-existing  business  relationships.  All purchasers were
provided  access to all  material  information,  which they  requested,  and all
information  necessary to verify such  information  and were afforded  access to
management of the Company in connection with their purchases.  All purchasers of
the unregistered securities acquired such securities for investment and not with
a view  toward  distribution,  acknowledging  such  intent to the  Company.  All
certificates  or  agreements  representing  such  securities  that  were  issued
contained restrictive legends,  prohibiting further transfer of the certificates
or agreements representing such securities, without such securities either being
first registered or otherwise exempt from  registration in any further resale or
disposition.

                                       14

<PAGE>

Item 3.  DEFAULTS UPON SENIOR SECURITIES

         None

Item 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         None

Item 5.  OTHER INFORMATION

         None

Item 6.  EXHIBITS

         The following is a complete list of exhibits filed as part of this Form
10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601
of Regulation S-K.

     31   Certification of Principal  Executive  Officer pursuant to Section 302
          of the Sarbanes-Oxley Act of 2002.

     32   Certification of Principal  Executive  Officer pursuant to Section 906
          of the Sarbanes-Oxley Act of 2002.


                                       15
<PAGE>



                                   SIGNATURES

         In accordance  with the  requirements  of Section 12 of the  Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized.

                                              CANCER DETECTION CORPORATION


                                                  /s/ David Kittrell
                                                  ------------------------------
Dated: April 16, 2009                         By: David Kittrell,
                                                  President, Principal Executive
                                                  Officer, & Principal Financial
                                                  Officer



















                                       16